年年
Lv5
888 积分
2022-12-18 加入
-
TP012/#1530 Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib in subjects with platinum sensitive recurrent ovarian cancer: flora-4
3天前
已完结
-
Randomized phase III trial on niraparib-TSR-042 (dostarlimab) versus physician’s choice chemotherapy in recurrent ovarian, fallopian tube, or primary peritoneal cancer patients not candidate for platinum retreatment: NItCHE trial (MITO 33)
3天前
已完结
-
A phase III, randomized, double blinded trial of platinum based chemotherapy with or without atezolizumab followed by niraparib maintenance with or without atezolizumab in patients with recurrent ovarian, tubal, or peritoneal cancer and platinum treatment free interval of more than 6 months: ENGOT-Ov41/GEICO 69-O/ANITA Trial
4天前
已完结
-
Phase Ib study of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients with platinum-resistant ovarian cancer
4天前
已完结
-
Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Characterization of antitumor activity in the SORAYA study
4天前
已完结
-
Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability–high tumors: A combined analysis of two cohorts in the GARNET study
4天前
已完结
-
A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer
4天前
已完结
-
Circulating small extracellular vesicle-based miRNA classifier for follicular thyroid carcinoma: a diagnostic study
6天前
已完结
-
Efficacy and safety of immune checkpoint inhibitors for individuals with advanced EGFR-mutated non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitors: a systematic review, meta-analysis, and network meta-analysis
11天前
已完结
-
Relapsed and refractory multiple myeloma: A systematic review and network meta‐analysis of the efficacy of novel therapies
12天前
已完结